

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **HANGZHOU TIGERMED CONSULTING CO., LTD.**

### **杭州泰格醫藥科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 3347)**

## **PROPOSED APPOINTMENT OF AN EXECUTIVE DIRECTOR AND PROPOSED AMENDMENT TO THE ARTICLES OF ASSOCIATION**

### **PROPOSED APPOINTMENT OF AN EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Directors**”, and each of them a “**Director**”) of Hangzhou Tigermed Consulting Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that on September 17, 2021, at the nineteenth meeting of the fourth session of the Board, Mr. Wu Hao (吳灝) (“**Mr. Wu**”) has been nominated as an executive Director candidate for the fourth session of the Board (the “**Proposed Appointment of Executive Director**”). The Proposed Appointment of Executive Director is subject to the approval by the ordinary resolution by the shareholders of the Company at the 2021 fifth extraordinary general meeting of the Company (“**EGM**”).

The biographical details of Mr. Wu are set out as follows:

**Mr. Wu Hao (吳灝)**, aged 54, joined the Group in January 2020 and is currently the co-president of our Company.

Mr. Wu has over 17 years of experience in the pharmaceutical industry and has extensive marketing and managerial experience. Prior to joining the Group, Mr. Wu served successively as sales manager and a product/project manager of Schering Plough Pharmaceutical Co., Ltd.\* (先靈葆雅製藥有限公司) from August 1994 to October 1999, product manager of Shanghai Roche Pharmaceutical Co., Ltd.\* (上海羅氏製藥有限公司) from October 1999 to December 2002, marketing director of Eisai China Inc.\* (衛材(中國)製藥有限公司) from January 2003 to July 2007, director of marketing and business development department of SciClone International Pharmaceutical Co., Ltd.\* (賽生國際製藥有限公司) from August 2007 to January 2009 and the general manager of Meixin Insurance Broker (Shanghai) Co., Ltd. (美信保險經紀(上海)有限公司) from March 2010 to January 2020.

Mr. Wu obtained his bachelor's degree in clinical medicine from Shanghai Jiao Tong University School of Medicine (formerly known as Shanghai Second Medical University) in 1992 and an EMBA degree from China Europe International Business School in 2009.

Mr. Wu has entered into an employment contract with the Company for a term of three years commencing on January 13, 2020 and ending on January 13, 2023. Mr. Wu will not enter into a separate employment contract with the Company in relation to his appointment as the executive Director. The term of office of Mr. Wu as executive Director shall commence from the date of passing of the relevant resolutions at the EGM until the conclusion of the fourth session of the Board and is eligible for re-election upon expiry of his term of office pursuant to the articles of association of the Company. The remuneration of Mr. Wu in relation to his role in the Company is determined by the Board according to the remuneration policy of the Company and with reference to his duties and responsibilities within the Group as well as his qualifications and experience. His remuneration was approximately RMB0.89 million (before tax) for the year ended December 31, 2020. Mr. Wu will not receive additional remuneration for his appointment as the executive Director.

Save as disclosed above, Mr. Wu has confirmed that, as at the date of this announcement, he (i) does not hold any directorship in any public companies, the securities of which are listed on any securities market in Hong Kong or overseas in the three years preceding the date of this announcement, (ii) does not have any relationship with any of the directors, general manager, supervisors, senior management, substantial shareholders or controlling shareholders of the Company as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), or (iii) does not hold any other position in the Company or any other member of the Group.

As at the date of this announcement, Mr. Wu does not have any interest in any shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, there is no other information that is required to be disclosed pursuant to any of the requirements under Rule 13.51(2)(h) to (v) of the Listing Rules, and there is no other matter relating to the appointment of Mr. Wu that needs be brought to the attention of the shareholders of the Company.

## **PROPOSED AMENDMENT TO THE ARTICLES OF ASSOCIATION**

In light of the Proposed Appointment of Executive Director, the Board has also proposed to make amendment to the relevant provision of the articles of association of the Company (the “**Articles of Association**”) to reflect the new structure of the Board after the appointment of the executive Director (the “**Proposed Amendment to the Articles of Association**”). The Proposed Amendment to the Articles of Association is subject to the approval of the special resolution by the shareholders of the Company at the EGM. The Board has also resolved to propose a resolution at the EGM to authorize the Board to delegate the management of the Company to handle the approval and filing procedures with relevant regulatory authorities, and to amend the wordings of the Proposed Amendment to the Articles of Association according to comments of the regulatory authorities (if any).

No.	Original article	Amended article
1	<b>Article 147</b> The board of directors shall comprise 6 directors and shall have one chairman and 3 independent directors. At least one of the independent directors must possess appropriate accounting or related financial management expertise.	<b>Article 147</b> The board of directors shall comprise <b>6</b> <u>7</u> directors and shall have one chairman and 3 independent directors. At least one of the independent directors must possess appropriate accounting or related financial management expertise.

Save for the abovementioned proposed amendment, other provisions of the Articles of Association shall remain unchanged. The Proposed Amendment to the Articles of Association are prepared in Chinese language. In the event of any discrepancy between the English translation and the Chinese version, the Chinese version shall prevail.

## GENERAL

A circular containing, among others, (i) the Proposed Appointment of Executive Director; (ii) the Proposed Amendment to the Articles of Association; and (iii) the notice convening the EGM will be despatched to the shareholders of the Company as and when appropriate.

By order of the Board  
**Hangzhou Tigermed Consulting Co., Ltd.**  
**Ye Xiaoping**  
*Chairman*

Hong Kong, September 17, 2021

*As at the date of this announcement, the executive Directors of the Company are Dr. Ye Xiaoping, Ms. Cao Xiaochun and Ms. Yin Zhuan; the independent non-executive Directors of the Company are Mr. Zheng Bijun, Dr. Yang Bo and Mr. Liu Kai Yu Kenneth.*

\* *For identification purposes only*